S-1: Panbela Therapeutics Files for Resale of 255,600 Shares by Selling Securityholders Amid Nasdaq Delisting

Panbela Therapeutics is registering the resale of up to 255,600 shares of its common stock by selling securityholders, while facing challenges with Nasdaq listing compliance.

Summary

• Panbela Therapeutics has filed a registration statement for the resale of up to 255,600 shares of its common stock by selling securityholders.
• These shares are issuable upon the exercise of Class D warrants issued in a private placement that closed on December 21, 2023.
• The exercise price of the warrants is $1.099 per share, but they are not exercisable until stockholder approval is obtained.
• The company will not receive any proceeds from the sale of these shares.
• Panbela's common stock is currently quoted on the OTC Pink Market under the symbol PBLA, with the last reported sale price on March 26, 2024, being $0.64 per share.
• The company is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum stockholders' equity requirement.
• Panbela is seeking opportunities to regain compliance or obtain an alternative listing on a national securities exchange.
• The company completed a 1-for-20 reverse stock split on January 18, 2024, and is seeking approval for another reverse stock split at a ratio between 1-for-10 and 1-for-45.
• The company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X) which provides a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmune disorders.
• The ASPIRE trial, a randomized double-blind placebo-controlled trial in combination with gemcitabine and nab-paclitaxel, a standard pancreatic cancer treatment regimen, in patients previously untreated for metastatic pancreatic cancer, has surpassed fifty percent enrollment and expects that the trial will be fully enrolled by the first quarter of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments in clinical trials and drug designations, the financial challenges, potential delisting, and need for additional capital raise concerns.

Positives

• The company has several ongoing clinical trials for its product candidates, including the ASPIRE trial for pancreatic cancer.
• Panbela has secured orphan drug designation for ivospemin from the FDA.
• The company has regained North American rights to develop and commercialize Flynpovi in patients with FAP.
• The ASPIRE trial has surpassed fifty percent enrollment and expects that the trial will be fully enrolled by the first quarter of 2025.

Negatives

• Panbela is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum stockholders' equity requirement.
• The company has a history of negative operating cash flow and has expressed substantial doubt regarding its ability to continue as a going concern.
• The company's common stock is currently trading on the OTC Pink Market, which may reduce liquidity and marketability.
• The company has had recurring losses from operations, negative operating cash flow and has an accumulated deficit.

Risks

• The company's ability to obtain additional capital is uncertain, which could restrict its ability to grow.
• The markets for the company's product candidates are highly competitive and subject to rapid scientific change.
• The company's lack of diversification increases the risk of an investment in the company.
• Clinical trials required for the company's product candidates are expensive and time-consuming, and their outcome is highly uncertain.
• The company relies on third parties for production of its product candidate and its dependence on these third parties may impair the advancement of our research and development programs and the development of our product candidates.
• Failure to maintain the listing of our common stock on a national securities exchange could seriously harm the liquidity of our stock and our ability to raise capital.

Future Outlook

The company is focused on continuing its clinical development programs, particularly the ASPIRE trial, and seeking regulatory approvals for its product candidates. Panbela is also evaluating options to regain compliance with Nasdaq listing requirements or obtain an alternative listing.

Industry Context

Panbela operates in the competitive biopharmaceutical industry, facing competition from larger companies with greater resources. The company's success depends on its ability to develop and commercialize innovative therapies for unmet medical needs, particularly in oncology.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• However, it mentions the use of gemcitabine and nab-paclitaxel as a standard pancreatic cancer treatment regimen, indicating that Panbela's approach is aligned with current clinical practices.
• The document also references the FDA approval of Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as a first-line treatment in adults living with metastatic pancreatic adenocarcinoma (mPDAC), suggesting that Panbela is aware of the latest advancements in the field.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and the risk of delisting from Nasdaq.
• Employees' job security could be affected by the company's financial stability.
• Patients may benefit from the development of new therapies for pancreatic cancer and other diseases.
• The company's suppliers and creditors face the risk of non-payment if Panbela's financial condition deteriorates.

Next Steps

• The company will seek stockholder approval for the Class D warrants.
• Panbela will continue to enroll patients in the ASPIRE trial and expects full enrollment by the first quarter of 2025.
• The company will evaluate options to regain compliance with Nasdaq listing requirements or obtain an alternative listing.
• The company is designing a Phase III registration trial for familial adenomatous polyposis (FAP).

Key Dates

Keywords

Panbela Therapeutics, common stock, resale, warrants, delisting, Nasdaq, ivospemin, Flynpovi, clinical trials, SBP-101, eflornithine, CPP-1X, reverse stock split, ASPIRE trial, orphan drug designation, FAP